# Epidemiology, clinical treatment and outcomes, susceptibility patterns and genotypic analysis of 214 Nocardia strains from multiple centers in Henan Province

**Authors:** Xiaogai Li, Cailin Liu, Yinyin Hu, Hui Xu, Haijun Li, Jingjing Sun, Xiangyang Chen, Yujuan Meng, Nan Zhang, Gongchang Li, Xiuping Lei, Limin Guo, Juhua Chen, Wanhai Wang

PMC · DOI: 10.3389/fcimb.2026.1728269 · Frontiers in Cellular and Infection Microbiology · 2026-02-13

## TL;DR

This study analyzed 214 Nocardia strains from Henan Province to understand their spread, treatment outcomes, and resistance patterns.

## Contribution

The study provides a comprehensive genotypic and phenotypic analysis of Nocardia strains from multiple hospitals in Henan Province.

## Key findings

- N. cyriacigeorgica was the most commonly isolated species, followed by N. farcinica.
- Most strains were susceptible to linezolid and trimethoprim-sulfamethoxazole.
- Antibiotic resistance and virulence genes varied significantly among species.

## Abstract

This study aimed to investigate the epidemiology, clinical treatment and outcomes, antimicrobial resistance profiles and genotypic analysis of 214 Nocardia strains collected from 9 hospitals in Henan Province spanning 9 years.

Through retrospective analysis of hospitalized patients with nocardiosis, the epidemiological characteristics of 214 Nocardia strains were elucidated. These isolates were identified and subjected to the broth microdilution method for the antimicrobial susceptibility profiles, and the resistance and virulence genes were determined using whole-genome sequencing (WGS).

Of all strains, 74.8% were collected from lower respiratory tract specimens, and N. cyriacigeorgica was the most commonly isolated species (28%), followed by N. farcinica (24.8%), N. abscessus (7.9%), N. amamiensis (7.9%), N. otitidiscaviarum (7.5%). 93.9% were obtained from in-province patients, and Nanyang City (28.0%) was with the highest isolation rate in Henan Province. Simultaneously, all of the strains were susceptible to linezolid (LZD), and 99.1% susceptible to trimethoprim-sulfamethoxazole (TMP-SMX). The antibiotic resistance profiles of other antibiotics varied tremendously among different Nocardia species. Of all the patients, 108 (50.7%) received TMP-SMX monotherapy or multidrug regimen; moreover, 182 (85.5%) patients recovered after treatment. Notably, 12 antibiotic resistance genes and 11 virulence genes were identified, implicating the complexity of resistance and pathogenicity mechanisms. Meanwhile, the MDR rates for Nocardia species ranged from 68.8% in N. otitidiscaviarum to 17.7% in N. amamiensis. No strains exhibited the XDR and PDR phenotypes.

This study provides a comprehensive evaluation of the epidemiology, phenotypic and genotypic profiles, and clinical treatment of Nocardia species in Henan, China. TMP-SMX and LZD can be used respectively for the clinical routine and critical treatment of nocardiosis. Particular emphasis is placed on the fact that antibiotic resistance and pathogenicity are species - specific, therefore, the AST of Nocardia isolates should be conducted and standardized, and attempts should be made to monitor its resistance molecular mechanisms.

## Linked entities

- **Chemicals:** linezolid (PubChem CID 3929), trimethoprim-sulfamethoxazole (PubChem CID 358641)
- **Diseases:** nocardiosis (MONDO:0017776)

## Full-text entities

- **Genes:** CALCA (calcitonin related polypeptide alpha) [NCBI Gene 796] {aka CALC1, CGRP, CGRP-I, CGRP-alpha, CGRP1, CT}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}
- **Diseases:** Fever (MESH:D005334), neurological deficits (MESH:D009461), pleural effusion (MESH:D010996), hemoptysis (MESH:D006469), COPD (MESH:D029424), fatigue (MESH:D005221), Chest pain (MESH:D002637), tumors (MESH:D009369), chronic bronchitis (MESH:D029481), Diabetes (MESH:D003920), pulmonary disease (MESH:D008171), acute or chronic lung disease (MESH:D055370), Hepatitis B Virus (MESH:D006509), emphysema (MESH:D004646), meningeal irritation (MESH:D008580), chronic kidney disease (MESH:D051436), bronchial asthma (MESH:D001249), cerebral involvement (MESH:D002547), cirrhosis (MESH:D005355), headache (MESH:D006261), chronic liver disease (MESH:D008107), abscess (MESH:D000038), inflammatory (MESH:D007249), pulmonary infection (MESH:D012141), cutaneous and soft-tissue infections (MESH:D018461), HL (MESH:C538324), N. abscessus (MESH:D009165), skin (MESH:D012871), MDR (MESH:D018088), acute/coronary heart disease (MESH:D054058), brain abscess (MESH:D001922), fungal infections (MESH:D009181), chronic pulmonary diseases (MESH:D002908), skin and soft tissue (MESH:D017695), Nocardia colonization (MESH:D003108), wheezing (MESH:D012135), Nocardia infection (MESH:D009617), tuberculosis (MESH:D014376), pulmonary fibrosis (MESH:D011658), acute and chronic pulmonary diseases (MESH:D012120), Infection (MESH:D007239), XDR (MESH:D054908), pulmonary tuberculosis (MESH:D014397), PDR (MESH:C564461), toxicity (MESH:D064420), N. farcinica (MESH:C536108), cough (MESH:D003371), Hepatitis C Virus (MESH:D006526), anemia (MESH:D000740), hypoproteinemia (MESH:D007019), CL (MESH:D002971), bronchiectasis (MESH:D001987), death (MESH:D003643), immunodeficiency (MESH:D007153), hypertension (MESH:D006973)
- **Chemicals:** MFX (MESH:D000077266), TOB (MESH:D014031), Cefepime (MESH:D000077723), tetracyclines (MESH:D013754), AMC (MESH:D019980), TGC (MESH:D000078304), beta-lactam antibiotics (MESH:D008997), agar (MESH:D000362), Ciprofloxacin (MESH:D002939), Cefoxitin (MESH:D002440), DOX (MESH:D004318), CLR (MESH:D017291), FEP (MESH:D011138), aminoglycoside (MESH:D000617), alcohol (MESH:D000438), beta-lactam (MESH:D047090), steroid (MESH:D013256), IPM (MESH:D015378), TMP-SMX (MESH:D015662), MNO (MESH:D008911), macrolides (MESH:D018942), CRO (MESH:D002443), rifampicin (MESH:D012293), LZD (MESH:D000069349), quinolone (MESH:D015363), AMK (MESH:D000583), fluoroquinolones (MESH:D024841), CIP (-), glycerol (MESH:D005990)
- **Species:** Human immunodeficiency virus 1 (no rank) [taxon 11676], Nocardia abscessus (species) [taxon 120957], Nocardia transvalensis (species) [taxon 37333], Nocardia otitidiscaviarum (species) [taxon 1823], Nocardia nova (species) [taxon 37330], Micromonospora chokoriensis (species) [taxon 356851], Nocardia cyriacigeorgica (species) [taxon 135487], Nocardia (genus) [taxon 1817], Saccharopolyspora hordei (species) [taxon 1838], Escherichia coli (E. coli, species) [taxon 562], Neoizziella asiatica (species) [taxon 1077397], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Mycobacterium tuberculosis (species) [taxon 1773], Homo sapiens (human, species) [taxon 9606], Human immunodeficiency virus (species) [taxon 12721], Nocardia farcinica (species) [taxon 37329], Nocardia yamanashiensis (species) [taxon 209247]
- **Mutations:** M24S

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12945825/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12945825/full.md

## References

45 references — full list in the complete paper: https://tomesphere.com/paper/PMC12945825/full.md

---
Source: https://tomesphere.com/paper/PMC12945825